Baseline characteristics of patients with relapsing multiple sclerosis in asclepios phase 3 trials of ofatumumab versus teriflunomide

Authors
Category Primary study
JournalNeurology
Year 2019
This article has no abstract
Epistemonikos ID: aafeaee952205b835c1825b88effcc62d97eb40d
First added on: Feb 11, 2025